BackgroundIt is known that daily divided doses and high doses of iron increase hepcidin and reduce iron absorption.AimTo compare treatments of iron replacement every other day at low doses, once a day and twice a day in terms of their effectiveness and frequencies of side‐effects.MethodsFor 1 month, Group I received 270 mg ferrous sulphate twice a day (total elemental iron dose: 160 mg/day), Group II received 270 mg ferrous sulphate once a day (total elemental iron dose: 80 mg/day), and Group III received 270 mg ferrous sulphate every other day (total elemental iron dose: 80 mg/every other day). Intragroup and intergroup statistical analyses were carried out.ResultsHaemoglobin (Hb) increased significantly in all three groups (P = 0.00). The increase in Hb levels was similar among the groups (P = 0.09). Ferritin significantly increased in all three groups after the treatment (P = 0.00). The increase in ferritin in Group I was significantly higher than those in Groups II and III (P < 0.05). Gastrointestinal tract (GIS) side‐effects were also significantly higher in Group I in comparison to the others (P = 0.001).ConclusionsA low dosage of iron treatment every other day may be used in the place of providing iron once or twice every day with similar effectiveness and lower rates of GIS side‐effects.

(Turkey) between 2000 and 2016 were evaluated for this study. Only patients older than 18 years were included in the study. Characteristics were evaluated by reviewing patients' records retrospectively. Results: Of the 386 patients studied, 242 (62.7%) were male and 144 (37.3%) were female and the overall median age was 53 years (range: 18-92). The most common histological subtype of NHL was diffuse large B-cell lymphoma (DLBCL) (46.9%). In univariate analyses, advanced stage (III-IV), high-intermediate to high risk category disease based on IPI score, bone marrow involvement at diagnosis, haemoglobin levels below 10 g/dL, increased LDH levels, primary nodal involvement, the presence of B symptoms, the exigency of autologous bone marrow transplant, and not receiving rituximabbased chemotherapy regimens as the primary treatment were all associated with shorter overall survival. Conclusion: The prevalence, clinical characteristics, histopathological subtypes, treatment responses, and overall survival rates may differ because NHL is a heterogeneous disease group and may vary according to a geographical area. Therefore, treatment should be individualized according to disease subtype.

No abstract

Red cell distribution width (RDW) is a marker of chronic inflammation. Hepatic diseases are often associated with several hematological complications; therefore, high levels of RDW are seen in hepatic diseases. Given the fact that factors which cause non-alcoholic steatohepatitis such as inflammation, oxidative stress, free oxygen radicals, and inflammatory cytokines may have a role in the discrepancy in the erythrocyte volume, we aimed to investigate the relationship between RDW and hepatic enzymes and Grade of hepatic steatosis. A total of 120 patients with non-alcoholic steatohepatitis using abdominal ultrasonography which was performed by a gastroenterology specialist, were included in the study. Biochemical analysis, complete blood count, other blood tests were performed. Spearman's Rho correlation test was used to analyze the relationship between the parameters and p value was accepted significant if it's <0.05. As a result of our study, there was no significant relationship between RDW and liver steatosis degree (p: 0.704). Also, significant relationship was not found between RDW and alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT) and lactate dehydrogenase (LDH) ( p values were 0,223, 0,856, 0,318, 0,597, 0,195 consecutively). In our study, we tried to find an answer to if there is a relationship between RDW alterations and inflammation which takes place in the pathogenesis of non-alcoholic steatohepatitis. As a result, we found no significant correlation between the RDW values and the degree of steatosis of liver and also liver enzymes.

Hemolytic anemia is characterized by a decrease in the number of circulating erythrocytes due to an increase in their hemolysis. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common erythrocyte enzyme defects related to hemolysis. The G6PD enzyme abrogates the hemolysis of erythrocytes by protecting them against oxidative stress due to its involvement in the glutathione metabolism. G6PD enzyme deficiency-related hemolytic anemia may present as neonatal jaundice or become manifest due to exposure to infections, favism and medications later in life. Dapsone is a medication that is preferred by doctors in the treatment of many dermatological disorders such as pemphigus vulgaris, and leads to hemolysis in the presence of G6PD enzyme deficiency. In this type of non-immune hemolysis, haptoglobulin is low and Coombs' tests are negative. Hemolytic anemia, a serious complication that may appear subsequent to dapsone use, can be prevented by testing G6PD enzyme levels prior to dapsone therapy. In this case, we emphasized that the hemolytic anemia in the patient using dapsone may be due to G6PD enzyme deficiency.